Global News Hubb
Advertisement Banner
  • Home
  • Politics
  • Finance
  • Technology
  • Contact
No Result
View All Result
  • Home
  • Politics
  • Finance
  • Technology
  • Contact
No Result
View All Result
Wellnessnewshubb
No Result
View All Result
Home Politics

Bispecific antibody for multiple myeloma succeeds in mid-stage trial

admin by admin
December 11, 2022
in Politics


NEW ORLEANS — Researchers had hoped in recent years that a protein called GPRC5D might offer a new way to get the immune system to hunt down and destroy multiple myeloma cells. Now, the results of a Phase 2 study on a bispecific antibody targeting this protein offers confirmation.

The data, presented Saturday at the annual American Society of Hematology conferences, wowed a crowd of attendees, including clinicians who began excitedly imagining how to use the new drug in practice.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED





Source link

Previous Post

Indian Overseas Bank revises interest rates on domestic, foreign currency

Next Post

Saudi minister says ‘all bets off’ if Iran gets nuclear weapon | Nuclear Weapons News

Next Post

Saudi minister says ‘all bets off’ if Iran gets nuclear weapon | Nuclear Weapons News

Recommended

Hackers take over Robinhood Twitter account to promote BNB Chain scam token

10 hours ago

US ‘deeply concerned’ about Whelan, citizen detained in Russia | Prison News

2 months ago

© 2022 Global News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • Politics
  • Finance
  • Technology
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • Politics
  • Finance
  • Technology
  • Contact

© 2022 Global News Hubb All rights reserved.